Regulatory News
Tuesday, June 7, 2016
BRIEF-Immune Pharmaceuticals and Hadasit file a joint patent on oral use of anti-Eotaxin Monoclonal antibodies, including Bertilimumab
* Immune Pharmaceuticals and Hadasit file a joint patent on
oral use of anti-Eotaxin Monoclonal antibodies, including
Bertilimumab
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment